⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2607983 | 0.88 | CHRNA7 (0.42) | — | |
| SCHEMBL21573624 | 0.88 | CHRNA7 (0.42) | — | |
| SCHEMBL14027182 | 0.88 | CHRNA7 (0.42) | — | |
| SCHEMBL7318990 | 0.76 | — | — | |
| SCHEMBL7438188 | 0.76 | — | — | |
| SCHEMBL2420280 | 0.76 | — | — | |
| SCHEMBL12614597 | 0.76 | CHRNB2 (0.41) | — | |
| SCHEMBL14111918 | 0.76 | CHRNB2 (0.41) | — | |
| SCHEMBL12665769 | 0.76 | CHRNB2 (0.41) | — | |
| SCHEMBL12614959 | 0.76 | CHRNB2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239892-A1 | COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF | ARKUDA THERAPEUTICS (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2021151976-A1 | [(1,4,5-TRISUBSTITUTED-1H-PYRAZOL-3-YL)SULFANYL]ACETIC ACID DERIVATIVES, SALTS THEREOF, AND USE THEREOF AS HERBICIDAL INGREDIENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-05 | — | — | WO | disclosed |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| US-20170348294-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2017-12-07 | — | — | US | disclosed |
| US-9828642-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-20170334886-A1 | N-SUBSTITUTED 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE | CODEXIS, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS PHARMA AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150275303-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2015-10-01 | — | — | US | disclosed |
| US-20140228398-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20140171448-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG | 2012-07-05 | — | — | US | disclosed |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | NOVARTIS AG | 2012-06-21 | — | — | US | disclosed |
| US-20080188518-A1 | 5-Substituted Imidazoles | ASTRA ZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-7384954-B2 | 4-substituted imidazoles | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-20070105896-A1 | 4-Substituted imidazoles | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | US | disclosed |
| US-7214688-B2 | Compounds | ASTRAZENECA AB (SE) | 2007-05-08 | — | — | US | disclosed |